James Noble

As co-founder and chief executive of Adaptimmunne, Noble is at the forefront of a field of healthcare that uses the body’s own immune system to fight cancer, HIV and infectious diseases. It is already testing its science on solid tumours, and listed on Nasdaq in 2015. Noble, 59, became full-time chief executive in 2014 after the company was split from Immunocore.